177 related articles for article (PubMed ID: 24008319)
1. Erythropoietin activates cell survival pathways in breast cancer stem-like cells to protect them from chemotherapy.
Todaro M; Turdo A; Bartucci M; Iovino F; Dattilo R; Biffoni M; Stassi G; Federici G; De Maria R; Zeuner A
Cancer Res; 2013 Nov; 73(21):6393-400. PubMed ID: 24008319
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs.
Gewirtz DA; Di X; Walker TD; Sawyer ST
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2232-8. PubMed ID: 16609039
[TBL] [Abstract][Full Text] [Related]
3. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression.
Hedley BD; Allan AL; Xenocostas A
Clin Cancer Res; 2011 Oct; 17(20):6373-80. PubMed ID: 21750199
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human erythropoietin in combination with chemotherapy increases breast cancer metastasis in preclinical mouse models.
Hedley BD; Chu JE; Ormond DG; Beausoleil MS; Boasie A; Allan AL; Xenocostas A
Clin Cancer Res; 2011 Oct; 17(19):6151-62. PubMed ID: 21856770
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line.
Shi Z; Hodges VM; Dunlop EA; Percy MJ; Maxwell AP; El-Tanani M; Lappin TR
Mol Cancer Res; 2010 Apr; 8(4):615-26. PubMed ID: 20353997
[TBL] [Abstract][Full Text] [Related]
6. Does erythropoietin have a dark side? Epo signaling and cancer cells.
Sytkowski AJ
Sci STKE; 2007 Jul; 2007(395):pe38. PubMed ID: 17636183
[TBL] [Abstract][Full Text] [Related]
7. Wnt/β-Catenin Small-Molecule Inhibitor CWP232228 Preferentially Inhibits the Growth of Breast Cancer Stem-like Cells.
Jang GB; Hong IS; Kim RJ; Lee SY; Park SJ; Lee ES; Park JH; Yun CH; Chung JU; Lee KJ; Lee HY; Nam JS
Cancer Res; 2015 Apr; 75(8):1691-702. PubMed ID: 25660951
[TBL] [Abstract][Full Text] [Related]
8. Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells.
Behera R; Kumar V; Lohite K; Karnik S; Kundu GC
Carcinogenesis; 2010 Feb; 31(2):192-200. PubMed ID: 19926637
[TBL] [Abstract][Full Text] [Related]
9. Autocrine erythropoietin signaling inhibits hypoxia-induced apoptosis in human breast carcinoma cells.
Acs G; Chen M; Xu X; Acs P; Verma A; Koch CJ
Cancer Lett; 2004 Oct; 214(2):243-51. PubMed ID: 15363551
[TBL] [Abstract][Full Text] [Related]
10. A CD90(+) tumor-initiating cell population with an aggressive signature and metastatic capacity in esophageal cancer.
Tang KH; Dai YD; Tong M; Chan YP; Kwan PS; Fu L; Qin YR; Tsao SW; Lung HL; Lung ML; Tong DK; Law S; Chan KW; Ma S; Guan XY
Cancer Res; 2013 Apr; 73(7):2322-32. PubMed ID: 23382045
[TBL] [Abstract][Full Text] [Related]
11. Insulin like growth factor binding protein-7 reduces growth of human breast cancer cells and xenografted tumors.
Amemiya Y; Yang W; Benatar T; Nofech-Mozes S; Yee A; Kahn H; Holloway C; Seth A
Breast Cancer Res Treat; 2011 Apr; 126(2):373-84. PubMed ID: 20464481
[TBL] [Abstract][Full Text] [Related]
12. ERK- and Akt-dependent neuroprotection by erythropoietin (EPO) against glyoxal-AGEs via modulation of Bcl-xL, Bax, and BAD.
Shen J; Wu Y; Xu JY; Zhang J; Sinclair SH; Yanoff M; Xu G; Li W; Xu GT
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):35-46. PubMed ID: 19628748
[TBL] [Abstract][Full Text] [Related]
13. Elesclomol, counteracted by Akt survival signaling, enhances the apoptotic effect of chemotherapy drugs in breast cancer cells.
Qu Y; Wang J; Sim MS; Liu B; Giuliano A; Barsoum J; Cui X
Breast Cancer Res Treat; 2010 Jun; 121(2):311-21. PubMed ID: 19609669
[TBL] [Abstract][Full Text] [Related]
14. Oxygen breathing may be a cheaper and safer alternative to exogenous erythropoietin (EPO).
Burk R
Med Hypotheses; 2007; 69(6):1200-4. PubMed ID: 17493766
[TBL] [Abstract][Full Text] [Related]
15. Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal.
Zhou B; Damrauer JS; Bailey ST; Hadzic T; Jeong Y; Clark K; Fan C; Murphy L; Lee CY; Troester MA; Miller CR; Jin J; Darr D; Perou CM; Levine RL; Diehn M; Kim WY
J Clin Invest; 2014 Feb; 124(2):553-63. PubMed ID: 24435044
[TBL] [Abstract][Full Text] [Related]
16. Serum erythropoietin levels, breast cancer and breast cancer-initiating cells.
Bhat K; Sandler K; Duhachek-Muggy S; Alli C; Cheng F; Moatamed NA; Magyar CE; Du L; Li G; McCloskey S; Vlashi E; Pajonk F
Breast Cancer Res; 2019 Jan; 21(1):17. PubMed ID: 30700319
[TBL] [Abstract][Full Text] [Related]
17. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
18. Autophagy Differentially Regulates Distinct Breast Cancer Stem-like Cells in Murine Models via EGFR/Stat3 and Tgfβ/Smad Signaling.
Yeo SK; Wen J; Chen S; Guan JL
Cancer Res; 2016 Jun; 76(11):3397-410. PubMed ID: 27197172
[TBL] [Abstract][Full Text] [Related]
19. Erythropoietin drives breast cancer progression by activation of its receptor EPOR.
Chan KK; Matchett KB; Coulter JA; Yuen HF; McCrudden CM; Zhang SD; Irwin GW; Davidson MA; Rülicke T; Schober S; Hengst L; Jaekel H; Platt-Higgins A; Rudland PS; Mills KI; Maxwell P; El-Tanani M; Lappin TR
Oncotarget; 2017 Jun; 8(24):38251-38263. PubMed ID: 28418910
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of the potential cancer stem-like cell marker Rex-1 improves chemotherapeutic effects in gliomas.
Kim BS; Kang KS; Choi JI; Jung JS; Im YB; Kang SK
Hum Gene Ther; 2011 Dec; 22(12):1551-62. PubMed ID: 21810014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
